Intensity-modulated Radiotherapy With Simultaneous Integrated Boost to Dominant Intraprostatic Lesion
Authors:
- Edy IppolitoEdy Ippolito
- Giovanna MantiniGMGiovanna Mantini
- Alessio G. MorgantiAMAlessio G. Morganti
- Ercole MazzeoEMErcole Mazzeo
- Gilbert D.A. PadulaGPGilbert D.A. Padula
- Cinzia DigesùCDCinzia Digesù
- Savino CillaSCSavino Cilla
- Vincenzo FrascinoVFVincenzo Frascino
- Stefano LuziSLStefano Luzi
- Mariangela MassaccesiMMMariangela Massaccesi
- Gabriella MacchiaGMGabriella Macchia
- Francesco DeodatoFDFrancesco Deodato
- 1 April 2012
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 35 (2) , 158-162
Abstract
To evaluate the feasibility of intensity-modulated radiotherapy with simultaneous integrated boost to the dominant intraprostatic lesion for definitive treatment of prostate cancer. Patients were deemed eligible for the study if they had histologically proven stage cT2-T3 N0M0 prostate adenocarcinoma. In addition <20% risk of lymph nodal involvement according to Roach formula, was required for enrollment. Patients were treated with intensity-modulated radiotherapy with simultaneous integrated boost technique to the dominant intraprostatic lesion defined by magnetic resonance imaging. The prescribed dose to the prostate and seminal vesicles was 72 Gy (1.8 Gy per fraction). The dose delivered to the intraprostatic lesion received was 80 Gy (2 Gy per fraction). Acute gastrointestinal (GI) and genitourinary (GU) toxicity was evaluated weekly during treatment, and at 1 and 3 months thereafter. Late GI and GU toxicity was evaluated by Kaplan Meier method. Forty patients were deemed evaluable. Acute and late GI and GU toxicity were evaluated in all patients. Two patients (5%) developed acute grade 3 GI toxicity and 1 patient (2.5%) developed acute grade 3 GU toxicity. No grade 4 acute GI or GU toxicity occurred. With a median follow-up of 19 months (interquartile range, 15 to 26 mo), the 2-year actuarial cumulative incidence of grade ≥2 rectal toxicity was 9.5%. The 2-year actuarial cumulative incidence of grade ≥2 urinary toxicity was 13.3%. Treatment related acute toxicity was low in our cohort. Prolonged observation with a larger series of patients is necessary to evaluate late toxicity and local control.Keywords
This publication has 25 references indexed in Scilit:
- Role of Intensity-Modulated Radiotherapy in Reducing Toxicity in Dose Escalation for Localized Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialThe Lancet Oncology, 2007
- Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the ProstateJAMA, 2005
- Magnetic resonance imaging anatomy of the prostate and periprostatic area: a guide for radiotherapistsRadiotherapy and Oncology, 2005
- The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapyRadiotherapy and Oncology, 2005
- Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 GyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planningInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCERJournal of Urology, 2001
- Determination of the Coefficient of CorrelationScience, 1909